Clinical trials: Localized Prostate Cancer
Prostate Cancer, Prostate Cancer Recurrent
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04102553
- Testing
- F-18-PSMA-1007, F-18-Fluorocholine
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Localized Intermediate Risk Prostate Lesions
Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity.
- Trial name
- NCT01657942
- Testing
- ExAblate MR Guided Focused Ultrasound
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- InSightec
Prostate Cancer
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
- Trial name
- NCT00050297
- Testing
- YM598
- Where
- 23 sites in Belgium, Czechia and 5 more
- Sponsor
- Astellas Pharma Inc
Localized Low-Intermediate Risk Prostate Cancer
Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study
The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has the potential to be a safe and effective non-invasive treatment for low to intermediate risk, organ-confined prostate cancer involving low…
- Trial name
- NCT01226576
- Testing
- MRgFUS Treatment
- Where
- 5 sites in Canada, Israel and 3 more
- Volunteers
- 8 people
- Sponsor
- InSightec
Bone Metastases
MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors
The objective of this trial is to evaluate the safety and effectiveness of MRgFUS in the treatment of metastatic bone tumors.
- Trial name
- NCT00350233
- Testing
- ExAblate 2000
- Where
- 2 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Prostate Cancer
Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA doubling times for patients with localized Prostate Cancer.
- Trial name
- NCT02107404
- Testing
- Dendritic Cells DCVAC/PCa
- Where
- 11 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- SOTIO a.s.
Prostate Cancer
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients…
- Trial name
- NCT03290508
- Testing
- Prolaris Testing
- Where
- 34 sites in United States
- Volunteers
- 524 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Localized Prostate Cancer
WATER IV Prostate Cancer
This is a multicenter, prospective, randomized clinical trial that aims to assess the safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for…
- Trial name
- WATER IV PCa (NCT06651632)
- Testing
- Aquablation Therapy, Radical Prostatectomy
- Where
- 37 sites in United States, Canada and 5 more
- Volunteers
- 280 people
- Sponsor
- PROCEPT BioRobotics
Prostate Cancer
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
- Trial name
- NCT01547299
- Testing
- Enzalutamide, Leuprolide, Dutasteride
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Pfizer
Prostate Cancer
Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer
This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can significantly postpone or eliminate the need of patients with organ confined intermediate risk prostate cancer to undergo a definitive treatment…
- Trial name
- NCT02968784
- Testing
- ExAblate MRgFUS
- Where
- 4 sites in Canada, China and 1 more
- Volunteers
- 53 people
- Sponsor
- InSightec
Prostatic Neoplasms
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk…
- Trial name
- PROTEUS (NCT03767244)
- Testing
- Apalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 2,517 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT)…
- Trial name
- NCT02531516
- Testing
- Apalutamide, Bicalutamide, GnRH (agonist)
- Where
- 263 sites in United States, Argentina and 21 more
- Volunteers
- 1,503 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer.
- Trial name
- PrTK03 (NCT01436968)
- Testing
- Aglatimagene besadenovec + valacyclovir
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 711 people
- Sponsor
- Candel Therapeutics, Inc.
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Prostate Cancer
High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Highly focused ultrasound energy may be able to kill cancer cells by heating the tumor without affecting the surrounding tissue.
- Trial name
- NCT00030277
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Focus Surgery
Neoplasms of the Prostate
An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue
To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
- Trial name
- NCT04240639
- Testing
- AuroShell particle infusion
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nanospectra Biosciences, Inc.
Prostate Cancer
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Background: GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear…
- Trial name
- NCT01176513
- Testing
- GE-148 (18F)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GE Healthcare